Focus: Hamilton Medical is a Swiss-based medical device company specializing in mechanical ventilators and respiratory care solutions, serving intensive care and acute care markets globally. With 501-1,000 employees, they operate as a established biotech/device manufacturer founded in 1983.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Hot — 91 jobs added in 30d
Net +80 (91 new, 11 removed). Aggressive expansion phase.
Limited upside for ambitious early-stage pharma careers, but stable operational roles available; core product safety concerns warrant diligence.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Multiple ANDA generic formulations in post-LOE phase; revenue negligible at $9K Part D spend.
Help build intelligence for Hamilton medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Hamilton medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Additional ANDA generic formulation with minimal Part D utilization.
Sodium salt formulation in post-LOE phase with no measurable Part D revenue.
Generic formulation in post-LOE phase with unquantified market presence.
Generic formulation in post-LOE phase with unquantified market presence.
Generic formulation in post-LOE phase with unquantified market presence.
Generic formulation in post-LOE phase with unquantified market presence.
Generic formulation in post-LOE phase with unquantified market presence.
9 discontinued, 9 duplicate formulations not shown
Recon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in China - RAPS
Recon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in China RAPS
FDA issues Class I recall for Hamilton Medical ventilator components - MassDevice
FDA issues Class I recall for Hamilton Medical ventilator components MassDevice
Hamilton Medical Recalls Breathing Circuit Set - Respiratory Therapy
Hamilton Medical Recalls Breathing Circuit Set Respiratory Therapy
No grafts, no scars: Inside the Hamilton medical breakthrough that saved an 18-year-old’s face - The Spec
No grafts, no scars: Inside the Hamilton medical breakthrough that saved an 18-year-old’s face The Spec
This Week at FDA: Upcoming Senate markup, first OTC CGM for children, and more - RAPS
This Week at FDA: Upcoming Senate markup, first OTC CGM for children, and more RAPS
Early Alert for Hamilton Medical Ventilator Breathing Circuit - respiratory-therapy.com
Early Alert for Hamilton Medical Ventilator Breathing Circuit respiratory-therapy.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Early changes of lung mechanics after positive end-expiratory pressure reduction in acute respiratory distress syndrome: a four-dimensional computed tomography study.
Pre-emptive and Prophylactic Strategies to Prevent Cardiovascular and Neurotoxicity in Chimeric Antigen Receptor T-Cell Therapy: The Role of Tocilizumab, Anakinra, and Cytokine-Targeted Interventions.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo